Fidelity Advisor Biotechnology A FBTAX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 33.27  /  −0.06 %
  • Total Assets 1.9 Bil
  • Adj. Expense Ratio
    0.960%
  • Expense Ratio 0.970%
  • Distribution Fee Level Low
  • Share Class Type Front Load
  • Category Health
  • Investment Style Mid Growth
  • Min. Initial Investment 0
  • Status Open
  • TTM Yield 0.94%
  • Turnover 73%

USD | NAV as of Oct 02, 2024 | 1-Day Return as of Oct 02, 2024, 10:20 PM GMT+0

Morningstar’s Analysis FBTAX

Will FBTAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

An upgrade in People Pillar rating is the primary driver of Fidelity Advisor Biotechnology A's upgrade to a Morningstar Medalist Rating of Gold from Silver.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBTAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 59.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

18.74 348.9 Mil
Healthcare

Amgen Inc

9.20 171.4 Mil
Healthcare

Regeneron Pharmaceuticals Inc

7.47 139.2 Mil
Healthcare

Alnylam Pharmaceuticals Inc

4.87 90.7 Mil
Healthcare

Vertex Pharmaceuticals Inc

4.59 85.5 Mil
Healthcare

argenx SE ADR

3.67 68.3 Mil
Healthcare

Ascendis Pharma AS ADR

3.53 65.7 Mil
Healthcare

Vaxcyte Inc Ordinary Shares

2.60 48.4 Mil
Healthcare

Viking Therapeutics Inc

2.47 46.0 Mil
Healthcare

Cytokinetics Inc

2.44 45.5 Mil
Healthcare

Sponsor Center